melanoma +Search for Videos


A melanoma
Oncology+ and dermatology+



In women, the most common site is the legs, and melanomas in men are most common on the back. It is particularly common among Caucasians+, especially northern Europe+ans and northwestern Europe+ans, living in sunny climates. There are higher rates in Oceania+, North America+, Europe+, Southern Africa, and Latin America+. This geographic pattern reflects the primary cause, ultraviolet light+ (UV) exposure in conjunction with the amount of skin pigmentation in the population. Melanocytes produce the dark pigment, melanin+, which is responsible for the color of skin. These cells predominantly occur in skin, but are also found in other parts of the body, including the bowel+ and the eye+ (see uveal melanoma+). Melanoma can originate in any part of the body that contains melanocytes.

The treatment includes surgical removal of the tumor. If melanoma is found early, while it is still small and thin, and if it is completely removed, then the chance of cure is high. The likelihood that the melanoma will come back or spread depends on how deeply it has gone into the layers of the skin. For melanomas that come back or spread, treatments include chemo-+ and immunotherapy+, or radiation therapy+. Five year survival rates+ in the United States are on average 91%.

Melanoma is less common than other skin cancers. However, it is much more dangerous if it is not found in the early stages. It causes the majority (75%) of deaths related to skin cancer.

Early signs of melanoma are changes to the shape or color of existing moles+ or, in the case of nodular melanoma+, the appearance of a new lump anywhere on the skin (such lesion+s should be referred without delay to a dermatologist). At later stages, the mole may itch+, ulcerate+ or bleed. Early signs of melanoma are summarized by the mnemonic "ABCDE":
* '''B'''orders (irregular)
*'''C'''olor (variegated)
*'''D'''iameter (greater than , about the size of a pencil eraser)
*'''E'''volving over time
These classifications do not, however, apply to the most dangerous form of melanoma, nodular melanoma, which has its own classifications:

*'''E'''levated above the skin surface
*'''F'''irm to the touch
Metastatic melanoma may cause nonspecific paraneoplastic symptoms+, including loss of appetite, nausea, vomiting and fatigue. Metastasis+ of early melanoma is possible, but relatively rare: less than a fifth of melanomas diagnosed early become metastatic. Brain metastases+ are particularly common in patients with metastatic melanoma. It can also spread to the liver, bones, abdomen or distant lymph nodes.

Melanomas are usually caused by DNA damage resulting from exposure to ultraviolet (UV) light from the sun.

The UV radiation from tanning beds increases the risk of melanoma. The International Agency for Research on Cancer+ finds that tanning beds are "carcinogenic to humans" and that people who begin using tanning devices before age 30 are 75% more likely to develop melanoma.

Those who work in airplanes also appear to have an increased risk, believed to be due to greater exposure to UV.

Ultraviolet UVB light+ (wavelengths between 315 – 280 nm) from the sun is absorbed by skin cell DNA and results in a type of direct DNA damage+ called cyclobutane pyrimidine dimers (CPDs)+, i.e. thymine-thymine, cytosine-cytosine or cytosine-thymine dimers that are formed by the joining of two adjacent pyrimidine+ bases within a strand of DNA. Somewhat similarly to UVB, UVA light+ (longer wavelengths between 400 – 315 nm) from the sun or from tanning beds can also be directly absorbed by skin DNA (at about 100 to 1000 fold lower efficiency than UVB is absorbed).

A number of rare mutations, which often run in families, are known to greatly increase one's susceptibility to melanoma. Several different genes+ have been identified as increasing the risk of developing melanoma. Some rare genes have a relatively high risk of causing melanoma; some more common genes, such as a gene called MC1R+ that causes red hair, have a relatively lower elevated risk. Genetic testing+ can be used to determine whether a person has one of the currently known mutations.

One class of mutations affects the gene CDKN2A+. An alternative reading frame+ mutation in this gene leads to the destabilization of p53+, a transcription factor+ involved in apoptosis+ and in fifty percent of human cancers. Another mutation in the same gene results in a nonfunctional inhibitor of CDK4+, a cyclin-dependent kinase that promotes cell division. Mutations that cause the skin condition xeroderma pigmentosum+ (XP) also seriously predispose one to melanoma. Scattered throughout the genome, these mutations reduce a cell's ability to repair DNA. Both CDKN2A and XP mutations are ''highly penetrant'' (meaning that the chances of a person carrying the mutation to express the phenotype is very high).

Familial melanoma is genetically heterogeneous, and loci for familial melanoma have been identified on the chromosome arms 1p, 9p and 12q. Multiple genetic events have been related to the pathogenesis (disease development) of melanoma. The multiple tumor suppressor+ 1 (CDKN2A/MTS1) gene encodes p16INK4a – a low-molecular weight protein inhibitor of cyclin-dependent protein kinases+ (CDKs) – which has been localised to the p21 region of human chromosome 9+.

Other mutations confer lower risk, but are more prevalent in the population. People with mutations in the MC1R gene, for example, are two to four times more likely to develop melanoma than those with two wild-type (typical unaffected type) copies of the gene. MC1R mutations are very common; in fact, all people with red hair have a mutated copy of the gene. Mutation of the MDM2 SNP309 gene is associated with increased risk of melanoma in younger women.

The earliest stage of melanoma starts when the melanocytes begin to grow out of control. Melanocytes are found between the outer layer of the skin (the epidermis+) and the next layer (the dermis+). This early stage of the disease is called the radial growth phase, and the tumor is less than 1 mm thick. Because the cancer cells have not yet reached the blood vessels lower down in the skin, it is very unlikely that this early-stage cancer will spread to other parts of the body. If the melanoma is detected at this stage, then it can usually be completely removed with surgery.

When the tumor cells start to move in a different direction — vertically up into the epidermis and into the papillary dermis+ — the behaviour of the cells changes dramatically.

The next step in the evolution is the invasive radial growth phase, which is a confusing term; however, it explains the next step in the process of the radial growth, when individual cells start to acquire invasive potential. This step is important – from this point on the melanoma is capable of spreading. The Breslow's depth+ of the lesion is usually less than , the Clark level+ is usually 2.

The following step in the process is the invasive melanoma — the vertical growth phase (VGP). The tumor attains invasive potential, meaning it can grow into the surrounding tissue and can spread around the body through blood or lymph vessels+. The tumor thickness is usually more than , and the tumor involves the deeper parts of the dermis.

The host elicits an immunological reaction against the tumor (during the VGP), which is judged by the presence and activity of the tumor infiltrating lymphocyte+s (TILs). These cells sometimes completely destroy the primary tumor; this is called regression, which is the latest stage of the melanoma development. In certain cases, the primary tumor is completely destroyed and only the metastatic tumor is discovered. About 40% of human melanomas contain activating mutations affecting the structure of the B-Raf+ protein, resulting in constitutive signaling through the Raf to MAP kinase+ pathway.

In general, cancers are caused by damage to DNA+. UVA light mainly causes thymine-thymine dimers. UVA also produces reactive oxygen species+ and these generate other DNA damages, primarily single strand breaks, oxidized pyrimidines and the oxidized purine 8-oxoguanine+ (a mutagenic DNA damage) at 1/10th, 1/10th and 1/3rd the frequencies of UVA-induced thymine-thymine dimers, respectively.

If unrepaired, CPD photoproducts can lead to mutations by inaccurate translesion synthesis+ during DNA replication or repair. The most frequent mutations due to inaccurate synthesis past CPDs are cytosine to thymine (C>T) or CC>TT transition mutations+. These are commonly referred to as UV fingerprint mutation+s, as they are the most specific mutation caused by UV, being frequently found in sun-exposed skin but rarely found in internal organs. Errors in DNA repair of UV photoproducts, or inaccurate synthesis past these photoproducts, can also lead to deletions, insertions and chromosomal translocation+s.

The entire genomes of 25 melanomas were sequenced (not only the protein-coding regions of the genome+ which are just 1% of the genome). On average, there were about 80,000 mutated bases (mostly C>T transitions) and about 100 structural rearragements per melanoma genome. This is a very high frequency, compared to the low mutation frequency of about 70 new mutations in the entire genome between generations (parent to child) in humans. Among the 25 melanomas, about 6,000 protein-coding genes had missense+, nonsense+ or splice site mutation+s.

Visual diagnosis of melanomas is still the most common method employed by health professionals. Moles that are irregular in color or shape are often treated as candidates of melanoma. To detect melanomas (and increase survival rates), it is recommended to learn what they look like (see "ABCDE" mnemonic below), to be aware of moles+ and check for changes (shape, size, color, itching or bleeding) and to show any suspicious moles to a doctor with an interest and skills in skin malignancy.

A popular method for remembering the signs and symptoms of melanoma is the mnemonic "ABCDE":
* ''A''symmetrical skin lesion.
* ''B''order of the lesion is irregular.
* ''C''olor: melanomas usually have multiple colors.
* ''D''iameter: moles greater than 6 mm are more likely to be melanomas than smaller moles.
* ''E''nlarging: Enlarging or evolving

A weakness in this system is the diameter. Many melanomas present themselves as lesions smaller than 6 mm in diameter; and all melanomas were malignant on day 1 of growth, which is merely a dot. An astute physician will examine all abnormal moles, including ones less than 6 mm in diameter. Seborrheic keratosis+ may meet some or all of the ABCD criteria, and can lead to false alarm+s among laypeople and sometimes even physicians. An experienced doctor can generally distinguish seborrheic keratosis from melanoma upon examination, or with dermatoscopy+.

Some advocate the system "ABCDE", with E for evolution. Certainly moles that change and evolve will be a concern. Alternatively, some refer to E as elevation. Elevation can help identify a melanoma, but lack of elevation does not mean that the lesion is not a melanoma. Most melanomas are detected in the very early stage, or in-situ stage, before they become elevated. By the time elevation is visible, they may have progressed to the more dangerous invasive stage.

Nodular melanoma+s do not fulfill these criteria, having their own mnemonic, "EFG":

* ''E''levated: the lesion is raised above the surrounding skin.
* ''F''irm: the nodule is solid to the touch.
* ''G''rowing: the nodule is increasing in size.

A recent and novel method of melanoma detection is the "ugly duckling sign". It is simple, easy to teach, and highly effective in detecting melanoma. Simply, correlation of common characteristics of a person's skin lesion is made. Lesions which greatly deviate from the common characteristics are labeled as an "Ugly Duckling", and further professional exam is required. The "Little Red Riding Hood" sign suggests that individuals with fair skin and light-colored hair might have difficult-to-diagnose amelanotic melanomas+. Extra care and caution should be rendered when examining such individuals, as they might have multiple melanomas and severely dysplastic nevi. A dermatoscope must be used to detect "ugly ducklings", as many melanomas in these individuals resemble non-melanomas or are considered to be "wolves in sheep clothing". These fair-skinned individuals often have lightly pigmented or amelanotic melanomas which will not present easy-to-observe color changes and variation in colors. The borders of these amelanotic melanomas are often indistinct, making visual identification without a dermatoscope very difficult.

Amelanotic melanomas and melanomas arising in fair-skinned individuals (see the "Little Red Riding Hood" sign) are very difficult to detect, as they fail to show many of the characteristics in the ABCD rule, break the "Ugly Duckling" sign, and are very hard to distinguish from acne scarring, insect bites, dermatofibromas+, or lentigines+.

Following a visual examination and a dermatoscopic exam, or ''in vivo'' diagnostic tools such as a confocal microscope, the doctor may biopsy+ the suspicious mole. A skin biopsy+ performed under local anesthesia+ is often required to assist in making or confirming the diagnosis and in defining the severity of the melanoma. If the mole is malignant, the mole and an area around it need excision. Elliptical excisional biopsies may remove the tumor, followed by histological analysis and Breslow scoring. Punch biopsies+ are contraindicated in suspected melanomas, for fear of seeding tumor cells and hastening the spread of the malignant cells.

Total body photography, which involves photographic documentation of as much body surface as possible, is often used during follow-up of high-risk patients. The technique has been reported to enable early detection and provides a cost-effective approach (being possible with the use of any digital camera), but its efficacy has been questioned due to its inability to detect macroscopic changes. The diagnosis method should be used in conjunction with (and not as a replacement for) dermoscopic imaging, with a combination of both methods appearing to give extremely high rates of detection.

Melanoma is divided into the following types:

* Lentigo maligna+
* Lentigo maligna melanoma+
* Superficial spreading melanoma+
* Acral lentiginous melanoma+
* Mucosal melanoma+
* Nodular melanoma+
* Polypoid melanoma+
* Desmoplastic melanoma+
* Amelanotic melanoma+
* Soft-tissue melanoma+

See also:

* Melanoma with small nevus-like cells+
* Melanoma with features of a Spitz nevus+
* Uveal melanoma+

Lactate dehydrogenase+ (LDH) tests are often used to screen for metastases+, although many patients with metastases (even end-stage) have a normal LDH; extraordinarily high LDH often indicates metastatic spread of the disease to the liver. It is common for patients diagnosed with melanoma to have chest X-rays and an LDH test, and in some cases CT+, MRI+, PET+ and/or PET/CT scans. Although controversial, sentinel lymph node+ biopsies and examination of the lymph node+s are also performed in patients to assess spread to the lymph nodes. A diagnosis of melanoma is supported by the presence of the S-100 protein+ marker.
HMB-45+ is a monoclonal antibody that reacts against an antigen present in melanocytic tumors such as melanomas, and stands for Human Melanoma Black. It is used in anatomic pathology as a marker for such tumors.
The antibody was generated to an extract of melanoma. It reacts positively against melanocytic tumors but not other tumors, thus demonstrating specificity and sensitivity. The antibody also reacts positively against junctional nevus cells but not intradermal nevi, and against fetal melanocytes but not normal adult melanocytes.
HMB-45 is nonreactive with almost all non-melanoma human malignancies, with the exception of rare tumors showing evidence of melanogenesis (e.g., pigmented schwannoma, clear cell sarcoma) or tumors associated with tuberous sclerosis complex (angiomyolipoma and lymphangiomyoma).

''Further context on cancer staging+ is available at TNM+.''

Also of importance are the "Clark level+" and "Breslow's depth+", which refer to the microscopic depth of tumor invasion.

Melanoma stages:
5 year survival rates:

'''Stage 0''': Melanoma ''in situ'' (Clark Level I), 99.9% survival

'''Stage I / II''': Invasive melanoma, 89–95% survival
*T1a: Less than 1.0 mm primary tumor thickness, without ulceration, and mitosis < 1/mm2
*T1b: Less than 1.0 mm primary tumor thickness, with ulceration or mitoses ≥ 1/mm2
*T2a: 1.01–2.0 mm primary tumor thickness, without ulceration

'''Stage II''': High risk melanoma, 45–79% survival
*T2b: 1.01–2.0 mm primary tumor thickness, with ulceration
*T3a: 2.01–4.0 mm primary tumor thickness, without ulceration
*T3b: 2.01–4.0 mm primary tumor thickness, with ulceration
*T4a: Greater than 4.0 mm primary tumor thickness, without ulceration
*T4b: Greater than 4.0 mm primary tumor thickness, with ulceration

'''Stage III''': Regional metastasis, 24–70% survival
*N1: Single positive lymph node
*N2: Two to three positive lymph nodes ''or'' regional skin/in-transit metastasis
*N3: Four positive lymph nodes ''or'' one lymph node and regional skin/in-transit metastases

'''Stage IV''': Distant metastasis, 7–19% survival
*M1a: Distant skin metastasis, normal LDH+
*M1b: Lung metastasis, normal LDH
*M1c: Other distant metastasis ''or'' any distant metastasis with elevated LDH

''Based upon AJCC five-year survival from initial melanoma diagnosis with proper treatment.''

Minimizing exposure to sources of ultraviolet radiation (the sun and sunbeds), following sun protection measures and wearing sun protective clothing+ (long-sleeved shirts, long trousers, and broad-brimmed hats) can offer protection. In the past, use of sunscreen+s with a sun protection factor (SPF) rating of 50 or higher on exposed areas were recommended; as older sunscreens more effectively blocked UVA with higher SPF. Currently, newer sunscreen ingredients (avobenzone, zinc, and titanium) effectively block both UVA and UVB even at lower SPFs. However, there are questions about the ability of sunscreen to prevent melanoma. This controversy is well discussed in numerous review articles, and is rejected by most dermatologists. This correlation might be due to the confounding variable that individuals who used sunscreen to prevent burn might have a higher lifetime exposure to either UVA or UVB. See Sunscreen controversy+ for further references and discussions.
Using artificial light for tanning was once believed to help prevent skin cancers, but it can actually lead to an increased incidence of melanomas. Even though tanning beds emit mostly UVA, which causes tanning, it by itself might be enough to induce melanomas.

A good rule of thumb for decreasing ultraviolet light exposure is to avoid the sun between the hours of 9 a.m. and 3 p.m. or avoid the sun when one's shadow is shorter than one's height. These are rough rules, however, and can vary depending on locality and individual skin cancer risk.

Almost all melanomas start with altering the color and appearance of normal-looking skin. This area may be a dark spot or an abnormal new mole. Other melanomas form from a mole or freckle that is already present in the skin. It can be difficult to distinguish between a melanoma and a normal mole. When looking for danger signs in pigmented lesions of the skin, a few simple rules are often used.

Confirmation of the clinical diagnosis is done with a skin biopsy+. This is usually followed up with a wider excision of the scar or tumor. Depending on the stage, a sentinel lymph node+ biopsy is done, as well, although controversy exists around trial evidence for this procedure. Treatment of advanced malignant melanoma is performed from a multidisciplinary approach.

Excisional biopsies may remove the tumor, but further surgery is often necessary to reduce the risk of recurrence. Complete surgical excision with adequate surgical margin+s and assessment for the presence of detectable metastatic disease along with short- and long-term followup is standard. Often this is done by a wide local excision+ (WLE) with 1 to 2 cm margins. Melanoma-in-situ and lentigo malignas are treated with narrower surgical margins, usually 0.2 to 0.5 cm. Many surgeons consider 0.5 cm the standard of care for standard excision of melanoma-in-situ, but 0.2 cm margin might be acceptable for margin controlled surgery (Mohs surgery+, or the double-bladed technique with margin control). The wide excision aims to reduce the rate of tumor recurrence at the site of the original lesion. This is a common pattern of treatment failure in melanoma. Considerable research has aimed to elucidate appropriate margins for excision with a general trend toward less aggressive treatment during the last decades.

Mohs surgery has been reported with cure rate as low as 77% and as high as 98.0% for melanoma-in-situ. CCPDMA+ and the "double scalpel" peripheral margin controlled surgery is equivalent to Mohs surgery in effectiveness on this "intra-epithelial" type of melanoma.

Melanomas that spread usually do so to the lymph nodes+ in the area of the tumor before spreading elsewhere. Attempts to improve survival by removing lymph nodes surgically (lymphadenectomy+) were associated with many complications, but no overall survival benefit. Recently, the technique of sentinel lymph node+ biopsy has been developed to reduce the complications of lymph node surgery while allowing assessment of the involvement of nodes with tumor.

Biopsy of sentinel lymph nodes is a widely used procedure when treating cutaneous melanoma.

Neither sentinel lymph node biopsy nor other diagnostic tests should be performed to evaluate early, thin melanoma, including melanoma in situ, T1a melanoma or T1b melanoma ≤ 0.5mm.Citation American Academy of Dermatology American Academy of Dermatology February 2013 Five Things Physicians and Patients Should Question American Academy of Dermatology+ Choosing Wisely+: an initiative of the ABIM Foundation+ |page
Sentinel lymph node biopsy is often performed, especially for T1b/T2+ tumors, mucosal tumors, ocular melanoma and tumors of the limbs. A process called lymphoscintigraphy+ is performed in which a radioactive tracer is injected at the tumor site to localize the sentinel node(s). Further precision is provided using a blue tracer dye+, and surgery is performed to biopsy the node(s). Routine hematoxylin and eosin+ (H&E) and immunoperoxidase+ staining will be adequate to rule out node involvement. Polymerase chain reaction+ (PCR) tests on nodes, usually performed to test for entry into clinical trials, now demonstrate that many patients with a negative sentinel lymph node actually had a small number of positive cells in their nodes. Alternatively, a fine-needle aspiration+ biopsy may be performed and is often used to test masses.

If a lymph node is positive, depending on the extent of lymph node spread, a radical lymph node dissection will often be performed. If the disease is completely resected, the patient will be considered for adjuvant therapy.
Excisional skin biopsy+ is the management of choice. Here, the suspect lesion is totally removed with an adequate (but minimal, usually 1 or 2 mm) ellipse of surrounding skin and tissue. To avoid disruption of the local lymphatic drainage, the preferred surgical margin for the initial biopsy should be narrow (1 mm). The biopsy should include the epidermal, dermal, and subcutaneous layers of the skin. This enables the histopathologist+ to determine the thickness of the melanoma by microscopic examination. This is described by Breslow's thickness+ (measured in millimeters). However, for large lesions, such as suspected lentigo maligna, or for lesions in surgically difficult areas (face, toes, fingers, eyelids), a small punch biopsy in representative areas will give adequate information and will not disrupt the final staging or depth determination. In no circumstances should the initial biopsy include the final surgical margin (0.5 cm, 1.0 cm, or 2 cm), as a misdiagnosis can result in excessive scarring and morbidity+ from the procedure. A large initial excision will disrupt the local lymphatic drainage and can affect further lymphangiogram-directed lymphnode dissection. A small punch biopsy can be used at any time where for logistical and personal reasons a patient refuses more invasive excisional biopsy. Small punch biopsies are minimally invasive and heal quickly, usually without noticeable scarring.

High-risk melanomas may require adjuvant+ treatment, although attitudes to this vary in different countries. In the United States, most patients in otherwise good health will begin up to a year of high-dose interferon+ treatment, which has severe side effects, but may improve the patient's prognosis slightly. However British Association of Dermatologist guidelines on melanoma state that interferon is not recommended as a standard adjuvant treatment for melanoma. A 2011 meta-analysis showed that interferon could lengthen the time before a melanoma comes back but increased survival by only 3% at 5 years. The unpleasant side effects also greatly decrease quality of life.

In Europe, interferon is usually not used outside the scope of clinical trials.

Metastatic melanomas can be detected by X-rays, CT scans, MRIs, PET and PET/CTs, ultrasound, LDH testing and photoacoustic detection.

Various chemotherapy+ agents, including dacarbazine+ (also termed DTIC), immunotherapy+ (with interleukin-2+ (IL-2) or interferon+ (IFN)), as well as local perfusion, are used by different centers. The overall success in metastatic melanoma is quite limited. IL-2 (Proleukin+) was the first new therapy approved (1990 Europe, 1992 USA) for the treatment of metastatic melanoma in 20 years. Studies have demonstrated that IL-2 offers the possibility of a complete and long-lasting remission in this disease, although only in a small percentage of patients.

A new chemotherapy drug temozolomide+ was approved by the FDA in 1999.

By 2005 a number of new agents and novel approaches were under evaluation and showed promise.

In 2009 Clinical trial participation was considered the standard of care for metastatic melanoma.

Other options now approved by the FDA include ipilimumab+ (a biological immmunotherapy agent), BRAF inhibitor+s such as vemurafenib+ (2011) and dabrafenib+ (2013), and a MEK inhibitor+ Trametinib+ (2013)

Standard excision is still being done by most surgeons. Unfortunately, the recurrence rate is exceedingly high (up to 50%). This is due to the ill-defined visible surgical margin, and the facial location of the lesions (often forcing the surgeon to use a narrow surgical margin). The narrow surgical margin used, combined with the limitation of the standard "bread-loafing" technique of fixed tissue histology — result in a high "false negative" error rate, and frequent recurrences. Margin control (peripheral margins) is necessary to eliminate the false negative errors. If bread loafing+ is used, distances from sections should approach 0.1 mm to assure that the method approaches complete margin control.

Mohs surgery+ has been done with cure rate reported to be as low as 77%, and as high as 95% by another author. The "double scalpel" peripheral margin controlled excision method approximates the Mohs method in margin control, but requires a pathologist intimately familiar with the complexity of managing the vertical margin on the thin peripheral sections and staining methods.

Some melanocytic nevi, and melanoma-in-situ (lentigo maligna+) have resolved with an experimental treatment, imiquimod+ (Aldara) topical cream, an immune enhancing agent. Some dermasurgeons are combining the 2 methods: surgically excising the cancer and then treating the area with Aldara cream postoperatively for three months.

Radiation therapy+ is often used after surgical resection for patients with locally or regionally advanced melanoma or for patients with unresectable distant metastases. It may reduce the rate of local recurrence but does not prolong survival. Radioimmunotherapy+ of metastatic melanoma is currently under investigation.
Radiotherapy has a role in the palliation of metastatic melanoma.

Features that affect prognosis+ are tumor+ thickness in millimeters (Breslow's depth+), depth related to skin structures (Clark level+), type of melanoma, presence of ulceration, presence of lymphatic/perineural invasion+, presence of tumor-infiltrating lymphocyte+s (if present, prognosis is better), location of lesion, presence of satellite lesions, and presence of regional or distant metastasis+. Certain types of melanoma have worse prognoses but this is explained by their thickness+. Interestingly, less invasive melanomas even with lymph node metastases carry a better prognosis than deep melanomas without regional metastasis at time of staging. Local recurrences tend to behave similarly to a primary unless they are at the site of a wide local excision+ (as opposed to a staged excision or punch/shave excision) since these recurrences tend to indicate lymphatic invasion.

When melanomas have spread to the lymph node+s, one of the most important factors is the number of nodes with malignancy. Extent of malignancy within a node is also important; micrometastases in which malignancy is only microscopic have a more favorable prognosis than macrometastases. In some cases micrometastases may only be detected by special staining, and if malignancy is only detectable by a rarely employed test known as the polymerase chain reaction+ (PCR), the prognosis is better. Macrometastases in which malignancy is clinically apparent (in some cases cancer completely replaces a node) have a far worse prognosis, and if nodes are matted or if there is extracapsular extension, the prognosis is worse still.

When there is distant metastasis, the cancer is generally considered incurable. The five-year survival rate is less than 10%. The median survival is 6–12 months. Treatment is palliative+, focusing on life extension and quality of life+. In some cases, patients may live many months or even years with metastatic melanoma (depending on the aggressiveness of the treatment). Metastases to skin and lungs have a better prognosis. Metastases to brain, bone and liver are associated with a worse prognosis. Survival is better with metastasis in which the local of the primary tumor is unknown.

There is not enough definitive evidence to adequately stage, and thus give a prognosis for, ocular melanoma and melanoma of soft parts, or mucosal melanoma (e.g. rectal melanoma), although these tend to metastasize more easily. Even though regression may increase survival, when a melanoma has regressed, it is impossible to know its original size and thus the original tumor is often worse than a pathology report+ might indicate.


Generally, an individual's risk for developing melanoma depends on two groups of factors: intrinsic and environmental. "Intrinsic" factors are generally an individual's family history and inherited genotype+, while the most relevant environmental factor is sun exposure.

Epidemiologic+ studies suggest that exposure to ultraviolet+ radiation (UVA and UVB) is one of the major contributors to the development of melanoma. UV radiation causes damage+ to the DNA+ of cells, typically thymine+ dimerization, which when unrepaired can create mutation+s in the cell's gene+s. When the cell divides+, these mutations are propagated to new generations of cells. If the mutations occur in protooncogene+s or tumor suppressor gene+s, the rate of mitosis+ in the mutation-bearing cells can become uncontrolled, leading to the formation of a tumor+. Data from patients suggest that aberrant levels of activating transcription factor in the nucleus of melanoma cells are associated with increased metastatic activity of melanoma cells; studies from mice on skin cancer tend to confirm a role for activating transcription factor-2 in cancer progression. Occasional extreme sun exposure (resulting in "sunburn+") is causally related to melanoma. Melanoma is most common on the back in men and on legs in women (areas of intermittent sun exposure). The risk appears to be strongly influenced by socio-economic conditions rather than indoor versus outdoor occupations; it is more common in professional and administrative workers than unskilled workers. Other factors are mutation+s in or total loss of tumor suppressor gene+s. Use of sunbed+s (with deeply penetrating UVA rays) has been linked to the development of skin cancers, including melanoma.

Possible significant elements in determining risk include the intensity and duration of sun exposure, the age at which sun exposure occurs, and the degree of skin pigmentation+. Melanoma rates tend to be highest in countries settled by migrants from northern Europe+ that have a large amount of direct, intense sunlight that the people's skin aren't adapted to, most notably Australia+. Exposure during childhood is a more important risk factor than exposure in adulthood. This is seen in migration studies in Australia

Fair- and red-haired people, persons with multiple atypical nevi+ or dysplastic nevi+ and persons born with giant congenital melanocytic nevi+ are at increased risk.

A family history of melanoma greatly increases a person's risk because mutations in ''CDKN2A+'', ''CDK4+'' and several other genes have been found in melanoma-prone families. Patients with a history of one melanoma are at increased risk of developing a second primary tumor.

The incidence of melanoma has increased in the recent years, but it is not clear to what extent changes in behavior, in the environment, or in early detection are involved.

To understand how sunscreen can reduce sunburn and at the same time cause melanoma it is necessary to distinguish between direct DNA damage+ and indirect DNA damage+. Genetic analysis has shown that 92% of all melanoma are caused by the indirect DNA damage.
Although some people believe that dark-skinned people such as those of African descent cannot get sunburns, they are in fact susceptible, and should use sunscreen accordingly, as sunscreen has been proven to protect against other cancers such as squamous cell carcinoma and basal cell carcinoma.

Australia+ continues to experience a very high - and increasing - burden from melanoma; in 2012, ''deaths'' from melanoma were 7.3-9.8 per 100,000 population. In Australia, melanoma is the third most common cancer in either sex; indeed, its incidence is higher than for lung cancer+, although the latter accounts for more deaths. It is estimated that in 2012, more than 12,000 Australians were diagnosed with melanoma: given Australia's modest population, this is better expressed as 59.6 new cases per 100,000 population per year; >1 in 10 of all new cancer cases were melanomas Melanoma incidence in Australia is matter of significance, for the following reasons:
* Australian melanoma incidence has increased by more than 30 per cent between 1991 and 2009.
* Australian melanoma age-standardised incidence rates were, as of 2008, at least 12 times higher than the world average.
* Australian melanoma incidence is, by some margin, the highest in the world.
* Overall age-standardised cancer incidence in Australia is the highest in the world, and this is attributable to melanoma alone. Age-standardised overall cancer incidence is similar to New Zealand, but there is a statistically-significant difference between Australia and all other parts of the developed world including North America, Western Europe, and the Mediterranean.

Although melanoma is not a new disease, evidence for its occurrence in antiquity is rather scarce. However, one example lies in a 1960s examination of nine Peru+vian mummies, radiocarbon+ dated to be approximately 2400 years old, which showed apparent signs of melanoma: melanotic masses in the skin and diffuse metastases to the bones. -->

John Hunter+ is reported to be the first to operate on metastatic melanoma in 1787. Although not knowing precisely what it was, he described it as a "cancerous fungous excrescence". The excised tumor was preserved in the Hunterian Museum+ of the Royal College of Surgeons of England+. It was not until 1968 that microscopic examination of the specimen revealed it to be an example of metastatic melanoma. -->

The French physician René Laennec+ was the first to describe melanoma as a disease entity. His report was initially presented during a lecture for the Faculté de Médecine de Paris in 1804 and then published as a bulletin in 1806. -->
The first English language report of melanoma was presented by an English general practitioner from Stourbridge, William Norris in 1820. In his later work in 1857 he remarked that there is a familial predisposition for development of melanoma (''Eight Cases of Melanosis with Pathological and Therapeutical Remarks on That Disease''). Norris was also a pioneer in suggesting a link between nevi and melanoma and the possibility of a relationship between melanoma and environmental exposures, by observing that most of his patients had pale complexions. He also described that melanomas could be amelanotic and later showed the metastatic nature of melanoma by observing that they can disseminate to other visceral organs.

The first formal acknowledgment of advanced melanoma as untreatable came from Samuel Cooper+ in 1840. He stated that the only chance for a cure depends upon the early removal of the disease (i.e., early excision of the malignant mole) ...' More than one and a half centuries later this situation remains largely unchanged.

Pharmacotherapy research for unresectable or metastatic malignant melanoma offers new treatment possibilities. In addition to the advances with recently approved agents, ongoing research into combination therapy, such as dabrafenib and trametinib, may reveal a more effective and better-tolerated option for patients with metastatic melanoma. One important pathway in melanin+ synthesis involves the transcription factor MITF+. The MITF gene+ is highly conserved and is found in people, mice, birds, and even fish. MITF production is regulated via a fairly straightforward pathway. UV radiation+ causes increased expression of transcription factor p53+ in keratinocytes+, and p53 causes these cells to produce melanocyte-stimulating hormone+ (MSH), which binds to melanocortin 1 receptor+s (MC1R) on melanocytes+. Ligand-binding at MC1R receptors activates adenylate cyclase+s, which produce cAMP+, which activates CREB+, which promote MITF expression. The targets of MITF include p16+ (a CDK inhibitor+) and Bcl2+, a gene essential to melanocyte survival. It is often difficult to design drugs that interfere with transcription factors, but perhaps new drugs will be discovered that can impede some reaction in the pathway upstream of MITF.

Studies of chromatin+ structure also promise to shed light on transcriptional regulation in melanoma cells. It has long been assumed that nucleosomes+ are positioned randomly on DNA+, but murine+ studies of genes involved in melanin production now suggest that nucleosomes are stereotypically positioned on DNA. When a gene is undergoing transcription, its transcription start site is almost always nucleosome-free. When the gene is silent, however, nucleosomes often block the transcriptional start site, suggesting that nucleosome position may play a role in gene regulation.

Finally, given the fact that melanin helps protect skin cells from UV-induced damage, new melanoma prevention strategies could involve attempts to induce melanin synthesis in individuals who would otherwise get sunburns. Redheads, for example, do not tan because they have MC1R mutations. In mice, it has been shown that the melanin production pathway can be rescued downstream of MC1R.

About 60% of melanomas contain a mutation in the B-Raf gene+. Early clinical trials suggested that B-Raf inhibitors including Plexxicon's vemurafenib+ could lead to substantial tumor regression in a majority of patients if their tumor contain the B-Raf mutation. In June 2011, a large clinical trial+ confirmed the positive findings from those earlier trials.

In August 2011 Vemurafenib received FDA approval for the treatment of late-stage melanoma.

In June 2012 a study reported that patients taking a different B-Raf inhibitor+, Dabrafenib+, did better than patients taking a chemotherapy agent.

In May 2013 the US FDA+ approved dabrafenib as a single agent treatment for patients with BRAF V600E mutation-positive advanced melanoma.

Some researchers believe that combination therapies that simultaneously block multiple pathways may improve efficacy by making it more difficult for the tumor cells to mutate before being destroyed. In October 2012 a study reported that combining Dabrafenib with a '''MEK inhibitor+''' trametinib+ led to even better outcomes. Compared to Dabrafenib alone, progression-free survival was increased to 41% from 9%, and the median progression-free survival+ increased to 9.4 months versus 5.8 months. Some side effects were, however, increased in the combined study.

In January 2014, the FDA approved the combination of dabrafenib and trametinib for the treatment of patients with BRAF V600E/K-mutant metastatic melanoma.

Eventual resistance to BRAF and MEK inhibitors may be due to a cell surface protein known as EphA2+ which is now being investigated.

At the American Society of Clinical Oncology+ Conference in June 2010, the Bristol-Myers Squibb+ pharmaceutical company reported the clinical findings of their drug ipilimumab+. The study found an increase in median survival from 6.4 to 10 months in patients with advanced melanomas treated with the monoclonal ipilimumab, versus an experimental vaccine. It also found a one-year survival rate of 25% in the control group using the vaccine, 44% in the vaccine and ipilimumab group, and 46% in the group treated with ipilimumab alone. However, some have raised concerns about this study for its use of the unconventional control arm, rather than comparing the drug against a placebo or standard treatment. The criticism was that although Ipilimumab performed better than the vaccine, the vaccine has not been tested before and may be causing toxicity, making the drug appear better by comparison.

Ipilimumab was approved by the FDA in March 2011 to treat patients with late-stage melanoma that has spread or cannot be removed by

In June 2011, a clinical trial of ipilimumab plus dacarbazine+ combined this immune system booster with the standard chemotherapy drug that targets cell division. It showed an increase in median survival for these late stage patients to 11 months instead of the 9 months normally seen. Researchers were also hopeful that perhaps 10–20% of patients could live a long time. Some serious side-effects of revving up the immune system were seen in some patients. A course of treatment costs $120,000. The drug's brandname is Yervoy.

In clinical research setting other therapies, such as adoptive cell therapy or gene therapy+, may be tested.
Two kinds of experimental treatments developed at the National Cancer Institute+ (NCI), part of the National Institutes of Health (NIH) in the US, have been used in advanced (metastatic) melanoma with high success rates in terms of melanoma treatments.
The first treatment involves adoptive cell therapy (ACT) using TILs immune cells (tumor infiltrating lymphocytes) isolated from a patient's own melanoma tumor. These cells are grown in large numbers in a laboratory and returned to the patient after a treatment that temporarily reduces normal T cells in the patient's body. TIL therapy following lymphodepletion can result in durable complete response in a variety of setups. Up to date, the only medical center outside the USA that has managed to successfully implement this technology is Sheba Medical Center+ through "Ella Institute of Melanoma", found in Israel (objective response rates of 50%). The second treatment, adoptive transfer of genetically altered autologous lymphocytes, depends on delivering genes that encode so called T cell receptor+s (TCRs), into patient's lymphocytes. After that manipulation lymphocytes recognize and bind to certain molecules found on the surface of melanoma cells and kill them.

A new treatment that trains the immune system to fight cancer has shown modest benefit in late-stage testing against melanoma.
Sutent+ may be effective for patients with metastatic melanoma.

Advances in high resolution ultrasound scanning have enabled surveillance of metastatic burden to the sentinel lymph nodes. The Screening and Surveillance of Ultrasound in Melanoma trial (SUNMEL) is evaluating ultrasound as an alternative to invasive surgical methods.

In some countries oncolytic virotherapy methods are studied and used to treat melanoma. Oncolytic virotherapy is a promising branch of virotherapy+, where oncolytic viruses+ are used to treat diseases; viruses can increase metabolism, reduce anti-tumor immunity and disorganize vasculature.

*Melanotropin receptor+
*Uveal melanoma+ - melanoma of the eye

* in: ''Atlas histopatologii guzów skóry'' (

Diseases of the skin and appendages by morphology:
Skin tumors, nevi and melanomas:

Melanoma+ Melanoma (/ˌmɛləˈnoʊmə/; from Greek μέλας melas, "dark") is a type of skin cancer which forms from melanocytes (pigment-containing cells in the skin).
Melanoma inhibitory activity+ Melanoma-derived growth regulatory protein is a protein that in humans is encoded by the MIA gene.
Melanoma with features of a Spitz nevus+ Melanoma with features of a Spitz nevus (also known as a "Spitzoid melanoma") is a cutaneous condition characterized histologically with tissue similar to a spitz nevus and with overall symmetry and a dermal nodule of epithelioid melanocytes that do not mature with progressively deeper dermal extension.
 CD146+ CD146 (cluster of differentiation 146) also known as the melanoma cell adhesion molecule (MCAM) or cell surface glycoprotein MUC18, is a 113kDa cell adhesion molecule currently used as a marker for endothelial cell lineage.
 Melanoma Research+ Melanoma Research (print: ISSN 0960-8931, online: ISSN 1473-5636) is a peer-reviewed medical journal published by Lippincott Williams & Wilkins since 1991. The journal publishes current findings on melanoma.
 Cancer vaccine+ A cancer vaccine is a vaccine that either treats existing cancer or prevents development of a cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines.
Clear-cell sarcoma+ Clear-cell sarcoma (formerly known as malignant melanoma of the soft parts) is a rare form of cancer called sarcoma.
 Melanoma-associated leukoderma+ Melanoma-associated leukoderma is a cutaneous condition, and is a vitiligo-like depigmentation that can occur in patients with cutaneous or ocular melanoma.
CSPG4+ Chondroitin sulfate proteoglycan 4, also known as melanoma-associated chondroitin sulfate proteoglycan (MCSP) or neuron-glial antigen 2 (NG2), is a chondroitin sulfate proteoglycan that in humans is encoded by the CSPG4 gene.
Small-cell melanoma+ Small-cell melanoma, also known as melanoma with small nevus-like cells, is a cutaneous condition, a tumor that contains variably-sized, large nests of small melanocytes with hyperchromatic nuclei and prominent nucleoli.